Maura Garofalo

Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Management of transthyretin amyloidosis

Swiss Medical Weekly, 20 ottobre 2021

2) Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction

Journal of Medical Chemistry, 23 settembre 2021

3) Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity

Nature Communications, 10 giugno 2021

4) Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Swiss Medical Weekly, 5 dicembre 2020

Facts & figures

Maura Garofalo has coordinated or participated in 4 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) whose subjects can be represented by this 6 elements tag cloud:

amyloidosis (3) immunoglobulin (1) inflammatory reactions (1) leukocyte (1) machine learning (1) peptide inhibitors (1)

Maura Garofalo has coordinated or participated in 4 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) featured by 3 scientific journals:

Swiss Medical Weekly (3) Journal of Medical Chemistry (1) Nature Communications (1)

Maura Garofalo has coordinated or participated in 4 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) involving also 21 co-authors being active in Ticino:

Andrea Cavalli (5) Chiara Kessler (3) Adalgisa Condoluci (3) Manuela Averaimo (3) Giorgio Treglia (3) Luca Mazzucchelli (3) Luca Varani (2) Jacopo Sgrignani (2) Luca Simonelli (1) Gabriela Danelon (1) Sara Ravasio (1) Milos Matkovic (1) Antonio Lanzavecchia (1) Valentina Cecchinato (1) Mariagrazia Uguccioni (1) Gianluca D’Agostino (1) Enrico M. A. Fassi (1) Raoul De Gasparo (1) Mathilde Foglierini (1) Bernhard Gerber (1) Mattia Pedotti (1)

Maura Garofalo has coordinated or participated in 4 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) in whose synopsis the 13 most frequently used terms (excluding 20 not relevant terms) are here listed:

M.G. WORD CLOUD amyloidosis (2) san (1) al-amyloidosis (1) analyses (1) antibody (1) somatic (1) mutations (1) immunoglobulin (1) toxicity (1) peptide (1) cxcl (1) hmgb (1) transthyretin (1)

In the synopsis of the whole 3332 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations), the 197 most frequently used terms (excluding 20 not relevant or unfrequently used terms (terms used less than 10 times) are here listed:

THE WHOLE WORD CLOUD cancer (299) covid- (186) thyroid (111) pet (109) cardiac (107) prostate (107) sars-cov- (103) hiv (89) atrial (81) breast (81) coronary (79) sclerosis (76) fibrillation (69) lymphoma (68) pandemic (67) bone (54) aortic (52) heart (51) artery (51) stroke (50) liver (47) carcinoma (46) brain (44) antibodies (42) cardiovascular (41) lung (40) mri (39) transcatheter (36) metastatic (35) dna (35) ventricular (35) kidney (34) nodules (34) tumor (33) extracellular (33) virus (33) myocardial (32) knee (31) ultrasound (30) oncology (30) mitral (27) antibody (27) esmo (27) percutaneous (26) f-fdg (26) hepatitis (25) vesicles (25) spinal (25) antiplatelet (24) cervical (24) ischemic (24) osteoarthritis (23) tuberculosis (23) diabetes (23) infarction (23) chemotherapy (23) ovarian (22) sentinel (22) radiotherapy (22) bladder (22) pulmonary (22) sperm (22) ehra (22) endovascular (21) implantation (21) transplantation (21) vaccination (21) renal (21) blood (20) lymph (19) resonance (19) plasma (19) tomography (19) urinary (19) bacterial (19) b-cell (18) monoclonal (18) nuclear (18) tumors (18) pacing (18) fdg (17) colorectal (17) laparoscopic (17) mice (17) implantable (16) autoimmune (16) vaccine (16) transplant (16) coronavirus (16) immunodeficiency (16) radiomics (15) membrane (15) preclinical (15) metabolic (15) metabolism (15) vascular (15) musculoskeletal (15) tricuspid (14) endometrial (14) pneumonia (14) antiretroviral (14) biomarker (14) serum (14) mrna (14) metastasis (14) lymphomas (14) fractures (14) peripheral (14) neurocognitive (14) leukemia (14) occlusion (13) male (13) behavior (13) muscle (13) interventions (13) legs (13) radiation (13) arterial (13) hemorrhage (13) nerve (13) biomarkers (13) pregnancy (13) lymphocytic (13) medullary (12) malignant (12) platelet-rich (12) hiv- (12) metastases (12) tau (12) iga (12) conference (12) mutations (12) malignancy (12) brugada (12) joint (12) fna (12) grafts (12) ischemia (12) dementia (12) esc (12) radiology (11) baseline (11) gastric (11) intravenous (11) arrhythmia (11) dynamic (11) incontinence (11) burden (11) pi (11) contemporary (11) contrast-enhanced (11) pathways (11) adherence (11) catheter (11) parkinson (11) limb (11) cytology (11) signaling (11) neck (11) mesenchymal (11) senescence (11) lockdown (11) il- (11) administration (10) overview (10) regurgitation (10) depression (10) art (10) idiopathic (10) clonal (10) bayesian (10) checkpoint (10) antithrombotic (10) precision (10) recovery (10) possible (10) prognosis (10) cancers (10) vascularized (10) adapted (10) peptide (10) ecg (10) infectious (10) fixation (10) prolapse (10) pci (10) hip (10) migraine (10) skin (10) prophylaxis (10) follicular (10) igg (10) vitamin (10) epidemiology (10) lipid (10) refractory (10) anesthesia (10)

Maura Garofalo has coordinated or participated in the 4 publications here listed (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations)

1) Management of transthyretin amyloidosis

2) Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction

3) Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity

4) Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Maura Garofalo has coordinated or participated in the 4 publications here listed
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations)